Gastrointestinal Therapeutics Market 2026 evolving with innovation

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Gastrointestinal Therapeutics Market At The End Of The 2026–2030 Forecast Period?

The gastrointestinal therapeutics market has experienced robust growth in recent years. It is projected to increase from $42.3 billion in 2025 to $44.72 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. The expansion observed in the historic period can be ascribed to factors such as the restricted availability of biologics and advanced gastrointestinal therapies, a rising incidence of acid reflux and ulcers, a dependency on hospital and clinic-based treatment, an increasing awareness concerning digestive health, and the prevailing use of traditional over-the-counter antacids and laxatives.

The gastrointestinal therapeutics market size is anticipated to undergo significant expansion in the coming years, with projections indicating it will reach $55.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. This growth throughout the forecast period is propelled by factors such as the creation of targeted biologics and immunotherapies, the increased availability of ambulatory surgical centers and diagnostic laboratories, a surge in the adoption of oral and intravenous delivery systems, the growing reach of online pharmacies, and innovations in probiotics and digestive enzyme formulations. Prominent trends for this period involve the rising occurrence of gastrointestinal disorders, a greater uptake of biologics and advanced therapies, the proliferation of over-the-counter therapeutics, an increasing focus on personalized gastrointestinal treatments, and the expanding distribution networks of online and retail pharmacies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

What Drivers Are Shaping The Future Growth Of The Gastrointestinal Therapeutics Market?

The increasing prevalence of inflammatory bowel diseases is anticipated to drive the expansion of the gastrointestinal therapeutics market going forward. Inflammatory bowel disease (IBD) describes a persistent ailment characterized by inflammation of the digestive system, encompassing conditions such as Crohn’s disease and ulcerative colitis. This rise in inflammatory bowel diseases stems from genetic predispositions, leading to an irregular immune reaction against gut microbes. Gastrointestinal therapeutics assist in the management and treatment of bowel conditions through addressing underlying inflammation, harmonizing digestive processes, and relieving accompanying symptoms, thereby enhancing patient well-being. As an illustration, in December 2023, data from the IBD Registry, a UK-based non-profit organization, indicated that more than 5,300 individuals with inflammatory bowel diseases (IBD) had registered in 2023, signifying an increase of over 3,000 members compared to 2022. Consequently, the growing occurrence of inflammatory bowel diseases is a key factor propelling the expansion of the gastrointestinal therapeutics market.

What Segment Types Make Up The Gastrointestinal Therapeutics Market?

The gastrointestinal therapeutics market covered in this report is segmented –

1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

Which Market Trends Are Creating New Opportunities In The Gastrointestinal Therapeutics Market?

Major companies in the gastrointestinal therapeutics market are concentrating on developing innovative treatments, such as sustained-release (SR) fixed-dose combination capsules, to enhance patient adherence and improve treatment effectiveness. Sustained-release (SR) fixed-dose combination capsules are oral medications engineered to gradually release multiple active ingredients over time, thereby maintaining consistent drug levels and reducing the frequency of dosing. For example, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, introduced rabeprazole + levosulpiride SR capsules for addressing gastrointestinal disorders in India. This formulation integrates rabeprazole, a proton pump inhibitor that reduces stomach acid, with levosulpiride, a prokinetic agent that improves gut motility. Together, they provide effective relief from symptoms such as heartburn, acid reflux, bloating, and indigestion. This specific combination is broadly prescribed for managing gastroesophageal reflux disease, peptic ulcers, and other related gastrointestinal (GI) conditions.

Who Are The Key Players Driving Competition In The Gastrointestinal Therapeutics Market?

Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

Read the full gastrointestinal therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

Which Geographic Regions Are Influencing Demand In The Gastrointestinal Therapeutics Market?

North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gastrointestinal Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25768&type=smp

Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2026, By The Business Research Company

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Digestive And Intestinal Remedies Market Report 2026

https://www.thebusinessresearchcompany.com/report/digestive-and-intestinal-remedies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795